Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

ZENB Expands Its Veggie Stick Line With New Pumpkin And Carrot Flavors


We are thrilled to introduce our new Pumpkin and Carrot flavors to consumers just in time for the fall season

ZENB, a plant-based food company that launched earlier this year, today announced the roll out of two new flavors in its Veggie Stick product line: Pumpkin and Carrot. The savory, fall-inspired Veggie Sticks bring ZENB fans a total of five flavor options as the company continues to innovate new ways to deliver wholesome vegetables in convenient snacking options.

The new Veggie Stick flavors, available year-round, boast 3-4g of fiber, 3g of protein and are less than 150 calories each per serving. By using organic, whole vegetables, ZENB’s Veggie Sticks offer a good source of daily fiber and clean ingredients in every Stick. As part of a commitment to using whole, fiber-rich vegetables, ZENB also incorporates parts of the vegetables that are often thrown away, like the seeds of the pumpkin and peel of the carrot. Thanks to a rigorous sourcing and manufacturing process, ZENB’s Veggie Sticks are gluten-free, vegan, and USDA organic, and offer consumers a clean label option for any occasion.

“We are thrilled to introduce our new Pumpkin and Carrot flavors to consumers just in time for the fall season. These flavors are sure to appeal with their savory taste profiles, colorful appearance and ode to the season,” says Christiane Paul, CMO of ZENB. “Moving forward, our commitment is to not only develop more Veggie Stick flavors like these, but also to provide a comprehensive line of plant-based, delicious products that fit into multiple dining occasions.”

Each Veggie Stick flavor offers a unique taste profile for an elevated snacking experience. Using the whole pumpkin, including skin and seeds, Pumpkin Veggie Sticks offer full-flavored veggie taste with a touch of cinnamon & nutmeg that’s perfect for the fall but can be enjoyed all year long. For on-the-go fiber and nutrition, the Carrot Veggie Sticks, made with the whole carrot, including the skin, offer the taste of organically grown carrots with a hint of flavorful coriander.

ZENB’s Veggie Sticks come in five distinct flavors: Corn, Beet, Red Bell Pepper, Carrot and Pumpkin. They are available all year direct-to-consumer via single sale and subscription boxes on ZENB.com, starting at $17.99 for a box of six. ZENB also offers a free trial pack (plus $4.99 shipping & handling and applicable tax) for veggie-lovers to try multiple flavors. Subject to terms and conditions, please see ZENB.com for more information.

About ZENB

ZENB is changing the way consumers think about nutrition by placing food that is wholesome and delicious at the center of everyday lives. By offering products that use often discarded parts of vegetables in each product, ZENB helps consumers enjoy plant-based foods in a way that is more mindful of the world around us. The company’s debut product, ZENB Veggie Sticks, are just the beginning of ZENB’s vision to empower a wholesome lifestyle filled with delicious, convenient options that incorporates a more plant-based diet. For more information about the ZENB community and product offerings, visit us at http://www.ZENB.com.

Share article on social media or email:

A ‘New Dawn’ in Treating Early Osteoarthritis of the Basal Joint


https://www.prweb.com/

Dr. Alejandro Badia

Until now, effective treatments for stopping the progression of osteoarthritis have been limited but increasing studies of the biological basis of the disorder are leading to new therapies, including application of protease inhibitors.

Scientists writing in a 2017 issue of European Medical Journal predicted that new, more effective therapeutic agents to stop the progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” Well, that day may already have dawned, says Miami-based hand and upper limb orthopedic surgeon Alejandro Badia, MD, founder and chief medical officer of the Badia Hand to Shoulder Center and OrthoNOW®, who is using advanced techniques, including natural biomaterials, to treat osteoarthritis of the thumb.

An expert in orthobiologics, Dr. Badia is harnessing the power of protease inhibitors to slow, and potentially halt, destruction of joint cartilage in the basal — carpometacarpal (CMC) – joint at the base of the thumb in patients with early osteoarthritis of the hand.

Orthobiologics involves utilizing a patient’s own biologic substances, or those of a donor, including blood platelets (PRP therapy) and adult (mesenchymal) stem cells, to mitigate inflammation, relieve chronic musculoskeletal pain and repair orthopedic injuries.

Dr. Badia explains that inflammation is a response to age-related wear-and-tear or injury to a joint and is believed to support the transition to pathological osteoarthritis. Although many factors can contribute to the development of osteoarthritis, nobody knows the primary cause of the debilitating disease. Many sedentary people develop this as they age, and both occupational and genetic factors play a part. It is certain however that repetitive and acute injuries, if untreated, will worsen the symptoms of underlying arthritis and accelerate its development and progression.

Researchers have determined that cartilage degradation is accelerated by chronic inflammation through the excessive activity of proteases, enzymes that normally function to clear damaged tissue after an injury but when they persist in chronically-inflamed joints they lead to degradation of cartilage and subsequent joint pain. Cartilage serves as a cushion for joints; its breakdown leads to joint stiffness and pain, Dr. Badia explains. Proteases are vital to many biological functions, such as digestion and cellular repair, but over-activity of these enzymes in the joint can speed the degradation of cartilage’s extracellular matrix.

But, protease inhibitors, like alpha 1-antitrypsin and alpha 2-macroglobulin, are molecules that can be harvested from blood plasma and other tissues to inhibit inflammatory proteases and clear them from the joint.

“Injection of these inhibitors into the basal joint is proving successful in some patients for relieving the debilitating pain of osteoarthritis of the thumb and potentially helping rebuild some of the lost cartilage,” says Dr. Badia. He and his team at OrthoNOW have treated arthritic patients using a variety of advanced surgical, non-surgical and orthobiologic approaches.

Osteoarthritis is the most common joint disease overall. Basal joint osteoarthritis, a specific form of the disorder, is the second most common arthritic condition of the hand, Dr. Badia says. The thumb disorder can result in severe pain, loss of grip function, strength and restricted range of motion and even deformity – to the point where a patient has difficulty holding a can or glass, opening a jar lid or buttoning a shirt, Dr. Badia notes.

Until now, effective treatments for stopping the progression of osteoarthritis have been limited but increasing studies of the biological basis of the disorder are leading to new therapies, including application of protease inhibitors.

Dr. Badia credits scientists like Shawn Browning Ph.D., vice president of research and development at Holding Technologies, who has studied the biology of joint cartilage degeneration in osteoarthritis, and medical innovators, such as Ziad Hamandi, chief executive officer of ABT Medical, for progress in treating osteoarthritis with protease inhibitors and other orthobiologics. Under Hamandi’s leadership, ABT Medical and their physician collaborators have designed advanced processes for separating blood and other fluid biologics into needed therapeutic components.

“The mission ABT Medical is to be innovative in the development of comprehensive blood management programs that are both responsive and reliable,” Hamandi states.

Orthobiologic therapies are not without risk, according to the federal Food and Drug Administration (FDA). Side effects can include reactions at site of injection, failure of biomaterials to perform as intended, and migration of injected cells away from treatment areas, potentially changing into unwanted cell types, multiplying, and negatively affecting other tissues.

Dr. Badia advises caregivers to exercise caution when administering biomaterials and exhorts patients to be especially careful when seeking medical help in the area of orthobiologics, a specialization in which practitioners often lack necessary training and expertise. It is imperative for patients who are considering regenerative medicine options to seek a clinician who can offer multiple remedies and solutions depending on the patient’s needs and stage of disease. In many cases, clinicians who have stem cell clinics are limited in what they can offer. OrthoNOW provides autologous access to stem cell therapies as well as other conservative therapies that the patient may benefit from, including anti-inflammatory mediators, physical therapy, procedures such as a joint arthroscopy, or even joint replacement for more severe cases. Dr. Badia worries that sometimes patients are being misled by practitioners who are not fully qualified to do regenerative medicine.

“Better than the best therapies for osteoarthritis, of course, is prevention,” states Dr. Badia. “You cannot stop joints from growing older, but you can reduce your risk for joint problems.” He offers the following recommendations:

  • Maintain an appropriate weight.
  • Keep joints heathy through exercise.
  • Control blood sugar.
  • Avoid joint injuries by wearing the proper protective gear when engaged in sports.

See an orthopedic specialist as soon as possible for diagnosis and treatment if a joint injury fails to heal. Injured joints are seven times more likely to develop osteoarthritis, according to the Arthritis Foundation.

Bio: Alejandro Badia, MD, FACS, internationally renowned hand and upper-limb surgeon and founder of Badia Hand to Shoulder Center and OrthoNOW®, a walk-in orthopedic care clinic. He is a member the American Society for Surgery of the Hand, American Association for Hand Surgery, and the American Academy of Orthopedic Surgeons. He is a specialist in treating all problems related to the hand and upper extremity including trauma, sports injury, joint reconstruction, nerve injuries and arthroscopic surgeries. OrthoNOWcare.com and drbadia.com.

Dental Intelligence, Inc. Announces $34 Million in Series A Funding from K1 Investment Management


News Image

This significant investment will accelerate di.’s ability to continue developing new tools so that providers can perform better dentistry and do more of it. K1’s strong operational capabilities and track record of building category leaders made them a perfect partner for us. Weston Lunsford, CEO

Dental Intelligence, Inc., the leading analytics and workflow automation platform for dental practices, announced today that it has raised a $34 million minority Series A growth round of funding from K1 Investment Management, a leading investment firm focusing on high-growth enterprise software companies.

Dental Intelligence (“di.”) launched in 2015 as a product to help dentists manage and grow their practices. Since then, the company has developed additional patient-focused applications driven by sophisticated analytics, including the Patient Finder, Morning Huddle, and Today’s Follow-Ups. In less than four years’ time, di.’s platform has been adopted by over 5,000 dental practices across the U.S., which have seen an average increase in topline production of over 50% after the first 12 months of usage.

“This investment marks a big milestone in di.’s growth,” said Weston Lunsford, co-founder and CEO of Dental Intelligence. “From the beginning, our company has had one simple purpose: helping dentists improve team performance, value, and overall culture in the practice. Everything we do emanates emotion, inspires engagement, and enables enrichment around that one purpose. This significant investment will accelerate di.’s ability to continue developing new tools so that providers can perform better dentistry and do more of it. K1’s strong operational capabilities and track record of building category leaders made them a perfect partner for us.”

A portion of the funding was used toward the recent acquisition of LocalMed, the industry leader in providing real-time, online appointment scheduling. Dental Intelligence will also use the investment to further develop and market existing and future products to individual, small group, and large enterprise practices due to increased demand across all customer segments.

“We are thrilled to partner with Weston and the Dental Intelligence team in this next chapter of growth and to support their mission of improving patient care,” said Kellen Haines, Vice President at K1. “Providing dentists with increased visibility into the performance of their practices and giving them the tools to be more successful in driving additional care is a win-win.”

In just over four years, Dental Intelligence has grown to over 150 team members with plans to bring on additional new hires throughout the company over 2019 and 2020.

“Dental Intelligence has experienced incredible revenue growth, having more than doubled since our initial underwriting,” added Taylor Beaupain, Managing Partner at K1 Investment Management. “K1’s investment, along with the company’s recent appointment to the Inc 5000 list of fastest-growing companies and the Utah Business Fast 50, provide continued recognition and validation of the company’s efforts to improve the lives and practices of dentists across the country.”

About Dental Intelligence

Dental Intelligence is the world’s smartest software used by thousands of dentists to manage and grow their practices. Dental Intelligence simplifies the team’s daily activities that are most important in improving patient health and increasing profitability in the practice. To learn more, visit http://www.dentalintel.com/

About LocalMed

LocalMed’s real-time online scheduling platform helps dental practices close the loop on all of their marketing efforts by connecting with potential patients wherever they’re searching: a practice’s website, Google, social media, insurance and product partners, etc. With LocalMed, a dental practice is open for scheduling anywhere, anytime, 24/7. Visit http://localmed.com to learn more.

About K1

K1 builds category-leading enterprise software companies. As a global investment firm, K1 assists high-growth businesses to achieve successful outcomes. K1 invests alongside strong management teams that continue to guide their organizations on a day-to-day basis. With over 85 professionals, K1 changes industry landscapes by assisting with operationally-focused growth strategies. Since the inception of the firm, K1 has partnered with over 110 enterprise software companies including industry leaders such as Apttus, Buildium, Certify, Checkmarx, ChiroTouch, Chrome River, Clarizen, ControlUp, Granicus, IronScales, Jobvite, Onit, Rave Mobile Safety, RFPIO, Smarsh and WorkForce Software. For more information about K1, please visit http://www.k1capital.com or http://www.linkedin.com/company/k1im.

Share article on social media or email:

Frame Park is the First National Demonstration Site to be Awarded Four NDS Designations


“We make a concerted effort to find ways to better respond to the community’s needs, especially when it comes to health and wellness,” according to City of Waukesha Parks, Recreation & Forestry (WPRF) Director Ron Grall.

Frame Park in Waukesha, Wisconsin is the first National Demonstration Site to be awarded four designations. This signature city park will allow the community to enjoy an outdoor adult fitness space and an inclusive playground that offers the six elements of play in a naturalized setting.

“We make a concerted effort to find ways to better respond to the community’s needs, especially when it comes to health and wellness,” according to City of Waukesha Parks, Recreation & Forestry (WPRF) Director Ron Grall. When proposed with the idea of becoming a National Demonstration Site, they gladly accepted the challenge. Out of the 30 playgrounds in the park system, they chose Frame Park to be the site for this project, as it is heavily-used and recognizable by the community and regional area. As the department reviewed the NDS designation options, they found it difficult to leave anything on the table as they each can offer unique benefits to the community in a variety of ways. The team reached out to Minnesota Wisconsin Playgrounds of Minneapolis, MN, to make their dreams come true. As a team trained in National Demonstration Site design, Minnesota Wisconsin was thrilled to be a part of the project.

Once extensive equipment plans were formalized with the NDS goals in mind, decisions needed to be made regarding the disposition of their existing playground equipment. Waukesha identified a way to bring the “joy of play” to communities in need by partnering with the Kids Around the World (KAW) program. KAW “harvested” and refurbished the old playground equipment with the end goal of relocating to a poverty-stricken area of the world. Following the playground “harvest”, WPRF held a “community build” September 3-5 with 182 community volunteers participating to bring their new space to life! The new play and fitness space also features a fully accessible poured-in-place rubber surfacing that exceeds current “fall factor” standards.

Grand Opening is scheduled for September 18, 2019 from 5-7 PM (CDT). Each National Demonstration Site designation area will be hosting individual activities, NatureGrounds will have a tree planting, DJ entertainment, community picnic, and tree identification; Outdoor Adult Fitness will have personal trainer sessions demonstrating safety tips and how to use the equipment; Inclusion and Play On! playground will have game sessions utilizing activities found in 2Play Together and Play On! to show families and the community how they can best utilize the play space. Waukesha plans to continue to program the space by adding the activity books to their public library for community use and will host a personal trainer session once a month from September to November.

Frame Park Playground-Fitness area is recognized as a project of excellence meeting the National Demonstration Site design criteria for inclusion, outdoor adult fitness, nature integration, and youth physical activity, and honored for their outstanding commitment and leadership to providing such a high-quality play and recreation destination.

To continue to celebrate WPRF’s commitment to advancing play and recreation through best practices, the department will receive a certificate of recognition, become a part of a network of potential research sites, and will be promoted actively to other communities wishing to create recreation spaces using design and/or programming. To locate the new site, check out http://www.playcore.com/nds/map.

About PlayCore:

PlayCore is a purpose driven Company committed to building stronger communities around the world by advancing play and recreation. The company infuses scholarly learning, through its Center for Outreach, Research, and Education, into its comprehensive family of brands. PlayCore combines best-in-class educational programming with the most comprehensive portfolio of play and recreation products and services to create tailored solutions that match the unique needs of each community served. Learn more at http://www.playcore.com.

Share article on social media or email:

Navigating Cancer, the Leader in Oncology Patient Relationship Management, Receives $26 Million in Oversubscribed New Funding


Navigating Cancer (NC), the leader in enabling personalized cancer care with its comprehensive oncology patient relationship management solution, announced today that it has received $26 million in Series D growth equity funding in an over-subscribed round led by the Merck Global Health Innovation Fund (GHIF) and TT Capital Partners (TTCP). The company’s end-to-end software platform, adopted by more than 1,700 cancer care providers domestically, uniquely connects providers and their patients throughout the care cycle.

Other investors in the round include BrightEdge, the American Cancer Society’s newly formed philanthropic venture fund; LabCorp®; ORIX Growth Capital; and Rustic Canyon Partners.

The funding will enable NC to accelerate innovation of its Patient Relationship Management (PRM) platform, including delivery of a more robust mobile experience for oncology patients and the development of NC’s AI-based population care capabilities. With NC’s platform, oncology practices are able to increase patient engagement, create a more responsive experience for cancer patients, and ultimately improve overall cancer care.

Forty Percent Growth Predicted in 2019

For 2019, Navigating Cancer is on pace to grow its oncology customer base by 40 percent. Accelerating adoption of NC’s unique platform is enabling more practices to succeed in delivering value-based care, a model that pays hospitals and physicians based on patient outcomes as opposed to fixed fees based on the service provided.

Navigating Cancer’s PRM platform helps providers manage patient interactions, improve the patient experience, and deliver value-based care more effectively – increasing the flow of communications between in-office visits, which, in turn, boosts patient engagement in their own care. NC’s platform also helps providers contain escalating costs. According to a study published in the Journal of Oncology Practice, two community cancer centers utilizing NC’s PRM platform generated significant cost savings due to better symptom management, while reducing emergency room visits by seven percent.

“This investment from these leading healthcare organizations really affirms the work that Navigating Cancer is doing to improve patient care and the success we’re seeing in helping oncology providers make the shift to value,” said Bill Bunker, the CEO of Navigating Cancer. “I’m excited about the innovations we’re making in areas like patient-reported outcomes and population care and the potential they have to further improve patient outcomes and satisfaction.”

“Oncologists must care for patients in an extremely complex regulatory and reimbursement environment, while managing a rapidly expanding number of therapy choices and effects across indications,” said David M. Rubin, Ph.D., Managing Director of Merck GHIF. “We’re delighted to continue our investment in this comprehensive patient care platform.”

Specifically, patients using the PRM platform can send messages to their doctor, receive reminders to take their medications, and report symptoms via a mobile app. Care providers, meanwhile, can triage patient needs; assess and manage symptoms and side effects; and streamline communications and care coordination for quicker responses.

Going forward, innovation in the PRM platform will incorporate artificial intelligence to support the assessment of patients at risk for various issues and identify proactive interventions to help improve care.

“More and more oncology practices are picking up the NC oncology platform because it’s a superb example of the heightened effectiveness created by leveraging 21st century technology in the practice of medicine,” said Bob Crutchfield, managing director of BrightEdge, the philanthropic impact fund of the American Cancer Society.

“As the dynamics of how providers, patients, and caregivers interact with one another continue to change in healthcare, Navigating Cancer’s platform represents a powerful example of technology enhancing the delivery of care and improving the overall healthcare experience,” said Tim Scallen, Principal at TT Capital Partners. “We look forward to collaborating with the management team to further extend Navigating Cancer’s platform reach and enhance the benefits it delivers to all cancer patients and providers.”

About Navigating Cancer

Navigating Cancer is the leading Patient Relationship Management technology and solutions company focused on improving the patient experience, delivering more effective care management and enabling oncology care innovation. With over 1,700 providers adopting the Navigating Care platform, it is the most broadly deployed patient management solution in oncology. The company’s products combine clinical workflows, oncology content and data insights to empower personalized care for cancer patients inside and outside of the clinic. For more information, please visit http://www.navigatingcancer.com or follow Navigating Cancer on Twitter @navcancer.

About TT Capital Partners

TT Capital Partners (TTCP) is a healthcare investor, collaborating with healthcare technology and services companies that have the potential to become market leaders. Leveraging the insights garnered from a unique knowledge-based platform, TTCP has invested in some of the most innovative, high-growth healthcare businesses. TTCP is part of the TripleTree healthcare merchant bank. For more information, visit TTCapitalPartners.com.

About BrightEdge

BrightEdge is the American Cancer Society’s donor-funded, philanthropic impact fund. The fund is led by a board comprised of the Society’s leaders and a management team with expertise in investment and venture capital. BrightEdge operates under a charitable fund model that invests in for-profit companies developing novel cancer-focused therapies and technologies. The fund relies on the expertise of the Society’s medical and science professionals to evaluate the mission value of its investments. The fund’s goal is to accelerate delivery of promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer. https://brightedgefund.org/.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenues of more than $11 billion in 2018. To learn more about LabCorp, visit http://www.LabCorp.com, and to learn more about Covance Drug Development, visit http://www.Covance.com.

VISTAAR Announces Addition of “ADVISORY Playbooks” to it’s Regulatory & Clinical Intelligence Platform


VISTAAR-Regulatory-Clinical-Intelligence

VISTAAR

Access Regulatory Guidance Documents with One Click

VISTAAR released ADVISORY Playbooks to help small and mid-level companies who need advisory either as a primary strategy or as re-assurance / 2nd opinion to their internal strategies they formed for developing or launching new products or expanding to new countries.

Lot of users when going into new markets, or planning to change their product elements and want to know the impact, introducing new product or to support their R&D teams, have ideas and thoughts but may not have a question clearly framed. VISTAAR while driving initial probing questions, you can give your needs or plans and VISTAAR than by leveraging its AI engine provides you a Regulatory strategy on what is needed, options, country requirements, forms/checklists, what other companies are doing in that scenario, what other products have those situations or parameters and more.

When someone cannot afford a senior consultant or need an initial pathway, these Playbooks can drive that process by significantly reducing the time and cost required compared to analyzing all the documents and information manually.

Try for a month FREE to test it for yourself. VISTAAR’s AI enabled Intelligence helps navigate today’s complex product development and regulatory landscape Better, Faster and Cheaper than any other regulatory and clinical intelligence platform. Visit http://www.vistaar.ai

Share article on social media or email:

Precision Botanical Launches the Purest CBD Brand Available That is Tested for Over 400 Contaminants Setting New Standards for All CBD Products


https://www.prweb.com/

Precision Botanical is the most rigorously tested brand in the CBD industry with each batch tested for more than 400 contaminants.

A new CBD brand that launched today seeks to disrupt the industry with its products’ transparency, purity, label accuracy and superiority. Colorado-based Precision Botanical enters the market as the only “Science First” CBD brand that was created by a team of U.S.-based neuroscientists, chemists and toxicologists. Precision Botanical products come from its own Oregon hemp farm and uses a commercial-level proprietary extraction of hemp oil that’s in the patent process. All products are third-party audited and certified for potency and purity.

Approximately 45% of the top 10 CBD brands’ products contain THC and third-party testing reveals that the top selling products are on average tested for fewer than 20 contaminants. In comparison, Precision Botanical tests all of its source material as well as finished products for more than 400 contaminants. This ensures Precision Botanical products are 99% pure, with accurate concentrations in each product and all are made with pharmaceutical-level precision. All of its products carry Clean Label Project Purity and THC-Free Certification.

Precision Botanical CBD products include its Soothe line. These topicals provide mess-free application and each one easily fits into a daily regimen. They contain functional, natural ingredients and were created for athletes by athletes. The Soothe line features:


  • Soothe Roll-on (MSRP $24.99 for 10 ml)
  • Soothe Salve (MSRP $44.99 for 1 oz)
  • Soothe Salve with Menthol (MSRP $44.99 for 1 oz)

Other product lines offered by Precision Botanical include its Calm, Renew, Alert and Sleep lines:

  • Renew Face Cream (MSRP $44.99 for 1 oz)
  • Renew Eye Cream (MSRP $ 44.99 for 1 oz)
  • Calm Tincture (MSRP $44.99 for 750mg, MSRP $19.99 for 300mg)
  • Calm Capsules (MSRP $44.99 for 30-count; MSRP $7.99 for 4-count)
  • Sleep Capsules (MSRP $54.99 for 60-count)
  • Gummies (MSRP $9.99 for 6 count; MSRP $19.99 for 20-count)
  • Alert Shot (MSRP $7.99 for 2oz)
  • Alert Capsules (MSRP 7.99 for 4-count)

Visit https://precisionbotanical.com/ to purchase all Precision Botanical products or to learn more.

About Precision Botanical

Denver, Colorado-based Precision Botanical is committed to quality, purity and transparency in creating the best CBD products available anywhere. It’s the only “Science First” CBD brand on the market founded by a team of neuroscientists, chemists and toxicologists. It also is the most rigorously tested brand in the CBD industry with each batch tested for more than 400 contaminants. All product comes from its 100-acre farm in the U.S. and both source materials and finished products are continually tested for purity and accuracy, providing consumers with the peace of mind they deserve.

Share article on social media or email:

Access Healthcare Appoints Jessica Cooley as Chief Marketing Officer


Jessica Cooley, Chief Marketing Officer, Access Healthcare

Jessica Cooley, CMO, Access Healthcare

The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.

Access Healthcare, one of the largest providers of healthcare revenue cycle management and IT services, today announced that Jessica Cooley has been appointed to the company’s executive leadership team as Chief Marketing Officer. In her new role, Cooley will spearhead the company’s global branding and marketing initiatives enabling the customer-facing sales efforts and building the teams towards executing the company’s strategic vision.

Cooley brings more than 17 years of experience in the healthcare industry and has a track record of generating significant profit, enhancing corporate credibility, and increasing market penetration. Prior to Access Healthcare, she was the Vice President of Strategic Accounts & Implementation for Provista, a Vizient subsidiary. While at Provista, she created and led the organization’s Strategic Accounts business unit, which now operates over $91 million in revenue responsibility. Cooley was instrumental in the ambulatory strategy development and execution as part of Provista’s long term growth plan. Cooley has earned several honors including President’s Circle 2016, Sales Excellence 2010, and Exceeding Excellence for 2003 and 2008.

“We are happy to welcome Jessica to our executive leadership team. Over the last few months, we’ve been focusing on building a strategy for how sales and marketing functions to enable the next phase of company’s growth,” says David Tassoni, President of US Operations of Access Healthcare. “We have been growing exponentially and Jessica’s deep marketing experience and strong business insights will bring significant opportunities for Access Healthcare and our business teams as we continue to move forward.”

“Access Healthcare is one of those brands that is revolutionizing the healthcare industry, and I’m truly excited to be part of this growing company,” says Cooley. “The critical part of my responsibility is to identify the untapped potential to narrate our success story and demonstrate what truly differentiates Access Healthcare to our providers and RCM companies in the marketplace.”

Cooley holds a B.S. in Human Development from Texas Tech University and is an active member of organizations such as the Young Men’s Service League, Professional Women in Healthcare, and the National Charity League.

About Access Healthcare

Access Healthcare provides business process outsourcing, applications services, and robotic process automation tools to healthcare providers, payers, and related service providers. The company operates from 19 delivery centers in the US, India and the Philippines, and its 12,000+ staff is committed to delivering revenue cycle excellence by leveraging technology, emerging best practices, and global delivery. Based in Dallas, Access Healthcare supports over 300,000 physicians, serves 80+ specialties, processes over $70 billion of A/R annually, and ascribes medical codes to over 30 million charts annually. To learn more, please visit http://www.accesshealthcare.com.

Share article on social media or email:

HIPAA One Raises Standard of Cybersecurity Controls Exclusively to Subscribers


These new cybersecurity questions elevate the standard of security satisfying the most-stringent security certifications while maintaining HIPAA compliance.

HIPAA One today announced a new set of HIPAA One Security risk analysis questions available exclusively to HIPAA One subscribers. These new questions come ahead of the new 42 CFR Part 2 coverage and updates to the final reporting engine coming later in Q4 2019.

Delivering on the promise of reducing the likelihood of breaches, HIPAA One’s new cybersecurity questions elevate the standard of security satisfying the most-stringent security certifications while maintaining HIPAA compliance.

“When we launched HIPAA One’s software platform, the goal was to simplify and reduce administrative burden in conducting and maintaining a HIPAA SRA by at least 80%,” said Steven Marco, President and CEO of HIPAA One. “Today we see gaps between the SRA and ever-evolving cybersecurity threats facing healthcare. Common-sense dictated leveraging HIPAA’s safeguards to evolve new standards for healthcare and its business associates. Now, subscribers can take advantage of this new functionality without any increase in fees while reducing cybersecurity risk to their organizations.”

New cybersecurity questions and supplied policies and procedures directly address:

•Data Classification and Data Loss Prevention 164.312(b)

•Systems Development Lifecycle (for business associates and in-house software development) 164.308(a)(8)

•Mobile Device Management & Mandatory Policy for BYOD (Bring your own Devices) 164.308(a)(5)(ii)(D), 164.310(d)(2)(ii), 164.312(a)(2)(iv)

•Change Management process as part of security evaluations 164.308(a)(8)

•Replacing weak passwords with passphrases or Multi-Factor Authentication (MFA) 164.312(d)

•Using the recently upgraded (and included) Vendor Management Solution (VMS) app, optionally requiring Business Associates provide evidence to satisfy the security requirements of a Covered Entity prior to providing the BAA contract for signing 164.308(b)(1), 164.308(b)(3).

These features are following the recently released Vendor Management Solution (VMS) that integrates business associate agreements into a streamlined, automated contract management system.

Visit https://www.hipaaone.com to learn more about our software and solutions.

ABOUT HIPAA ONE

HIPAA One is a simple, automated and affordable HIPAA compliance software solution. The HIPAA One suite allows healthcare providers, payers and business associates of all sizes to focus on their important objectives: core competencies, improving compliance and reducing operating costs. Designed for auditors seeking advanced functionality, partners and office managers alike, the software scales from the single-doc practice to enterprise organizations needing to simplify complex problems, provide macro-analytics and “always current” HIPAA controls. To learn more about HIPAA One® visit http://www.hipaaone.com.

Share article on social media or email:

Dr. Babis Rammos Partners with the Exclusive Haute Beauty Network


Dr. Babis Rammos, renowned plastic surgeon in Central Illinois, has joined the esteemed Haute Beauty network.

Dr. Babis Rammos, a renowned plastic surgeon in Central Illinois has joined the esteemed Haute Beauty network.

The Haute Beauty Network, well known for its exclusive and luxurious lifestyle publication Haute Living is privileged to present Dr. Babis Rammos as a body expert and our newest addition to the Haute Beauty members-only network.

Haute Beauty offers a prominent collective of leading doctors. The invitation-only exclusive publication maintains elite as ever, with only two doctors in every market. This partnership allows Haute Beauty to connect its affluent readers with industry-leading aesthetic surgeons located in their area.

Dr. Rammos is a Plastic and Reconstructive Surgeon at Illinois Cosmetic & Plastic Surgery. He performs cosmetic procedures including breast augmentation, abdominoplasty, mommy makeover, liposuction, facelift, buttocks augmentation and Botox and filler injections. He has authored numerous publications and book chapters on a variety of topics including facelift, browlift, body contouring, aesthetic breast surgery, and breast reconstruction.

Visit Dr. Babis Rammos’s Haute Beauty Profile – https://hauteliving.com/hautebeauty/member/babis-rammos-md-facs/

About Dr. Babis Rammos :

Dr. Rammos completed his General Surgery Residency Program at the University of Illinois and received the “Warren Cole Society” Award for recognition of outstanding Chief Resident Leadership and being an excellent role model for Fellow Residents. He then completed his plastic surgery training at the world-renowned Mayo Clinic in Minnesota. He spent an additional year in Charlotte, NC where he completed an Aesthetic Plastic Surgery Fellowship at the Hunstad/Kortesis Plastic Surgery Center, 1 of only 12 Fellowship Programs nationwide endorsed by the American Society for Aesthetic Plastic Surgery (ASAPS). Dr. Rammos is a Plastic and Reconstructive Surgeon at Illinois Cosmetic & Plastic Surgery. He performs cosmetic procedures including breast augmentation, abdominoplasty, mommy makeover, liposuction, facelift, buttocks augmentation and Botox and filler injections. He has authored numerous publications and book chapters on a variety of topics including facelift, browlift, body contouring, aesthetic breast surgery, and breast reconstruction. He has given national and international presentations on both aesthetic and reconstructive surgery. Dr. Rammos is an Assistant Professor of Surgery and the Vice Chairman of Research at the Department of Surgery at the University of Illinois at Peoria. He is board certified by the American Board of Surgery and the American Board of Plastic Surgery.

Explore more — https://www.hauteliving.com/hautebeauty

Share article on social media or email: